Source: International Congress 2015 – Novel targets and strategies for the treatment of cough, asthma, rhinosinusitis and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Gary P. Anderson (Parkville, Australia), Gary P. Anderson, Andreas Hohlbaum, Kristian Jensen, Alexandra Bähre, Hendrik Gille. Discovery of PRS-060, an inhalable CD123/IL4Ra/TH2 blocking anti-asthmatic anticalin protein re-engineered from endogenous lipocalin-1. Eur Respir J 2015; 46: Suppl. 59, 3256

Member's Comments

No comment yet.

Related content which might interest you: Characterization QAW039 and QAV680, two novel, potent and selective CRTh2 antagonists Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014 QAW039, a slowly dissociating CRTh2 antagonist with potential for improved clinical efficacy Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014 ALX-0962, an anti-IgE Nanobody® with a dual mode of action Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013 In vitro characterization of a novel inhaled PI3Kd inhibitor LAS194223 Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 In vitro pharmacological characterization of a novel p38α (MAPK14) inhibitor designed for inhaled delivery Source: International Congress 2016 – Novel insights into the treatment of COPD Year: 2016 In vitro profile of the new inhaled pan-JAK inhibitor LAS194046 Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Safety and pharmacology of a soluble epoxide hydrolase inhibitor Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 Novel, highly potent and selective JAK3 inhibitor disrupting IL-4/IL-13 signaling in asthma therapy Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 Therapeutic blockade of IL-4 and 13 signaling with dupilumab (SAR231893/REGN668) inhibits key biomarkers in asthma Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Safety, tolerability and pharmacokinetics of an oral competitive reversible CRTh2 antagonist, QAW039, in healthy subjects Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014 LSC 2014 abstract - Deciphering of the mechanism of the anti-asthmatic action of the CXCL12 neutraligand, chalcone 4 Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014 No shunting towards LTB4 when blocking LTC4s in vitro Source: International Congress 2015 – Therapeutic approaches in inflammatory lung disease Year: 2015 Therapeutic potential of CPL-407-105 – Novel potent JAK/STAT pathway inhibitor for the treatment of asthma Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Oct2 interaction with Brd4 is a key component of immunoglobulin gene expression Source: International Congress 2014 – Novel approaches to human studies in allergy and asthma Year: 2014 An antedrug of the CXCL12 neutraligand blocks experimental allergic asthma without systemic effect in the mouse Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013 Redefining the asthma treatment paradigm using a locally administered dual PI3Kgd inhibitor Source: International Congress 2016 – New therapies and therapeutic targets Year: 2016 The effect of oligomeric proanthocyanidin on airway microenvironment in asthma Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action Year: 2016 Enhanced anti-inflammatory gene expression in humans following inhaled budesonide Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders Year: 2013 Safety, tolerability and pharmacokinetics of QAV680, an oral CRTh2 antagonist, in healthy subjects Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014 Preclinical characterization of CPL-302-201, a novel, highly potent and selective PI3Kδ inhibitor for the treatment of inflammatory disorders Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014